Cargando…
Glycemic variability in type 2 diabetes mellitus and acute coronary syndrome: liraglutide compared with insulin glargine: a pilot study
OBJECTIVE: To explore the glucagon-like peptide-1 analogue liraglutide in the hospital setting in patients with type 2 diabetes mellitus (T2DM) and acute coronary syndrome and to evaluate the safety and efficacy and its impact on hospitalization and short-term glycemic variability (GV). METHODS: A 1...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7309403/ https://www.ncbi.nlm.nih.gov/pubmed/32567433 http://dx.doi.org/10.1177/0300060520926063 |
_version_ | 1783549199105654784 |
---|---|
author | del Olmo-García, Maria Isabel Hervás Marín, David Caudet Esteban, Jana Ballesteros Martin-Portugués, Antonio Cerveró Rubio, Alba Arnau Vives, Miguel Angel Catalá Gregori, Ana Penalba Martínez, Maite Merino-Torres, Juan Francisco |
author_facet | del Olmo-García, Maria Isabel Hervás Marín, David Caudet Esteban, Jana Ballesteros Martin-Portugués, Antonio Cerveró Rubio, Alba Arnau Vives, Miguel Angel Catalá Gregori, Ana Penalba Martínez, Maite Merino-Torres, Juan Francisco |
author_sort | del Olmo-García, Maria Isabel |
collection | PubMed |
description | OBJECTIVE: To explore the glucagon-like peptide-1 analogue liraglutide in the hospital setting in patients with type 2 diabetes mellitus (T2DM) and acute coronary syndrome and to evaluate the safety and efficacy and its impact on hospitalization and short-term glycemic variability (GV). METHODS: A 12-week, open-label, prospective, randomized pilot clinical study with parallel groups that compared liraglutide (group 1) with glargine (group 2) and its impact on glycemic control and GV. RESULTS: Thirteen patients were included. During hospitalization, mean glucose was 164.75 mg/dL (standard deviation [SD] 19.94) in group 1 and 166.69 mg/dL (38.22) in group 2. GV determined by CV and SD was 20.98 (7.68) vs. 25.48 (7.19) and 34.37 (13.05) vs. 43.56 (19.53) in groups 1 and 2, respectively. Group 1 prandial insulin requirements during hospitalization were lower compared with group 2. Follow-up A1c in group 1 was 6.9% (−1.51%) and 6.5% in group 2 (−1.27). GV after discharge and hypoglycemia were lower in group 1 compared with group 2. CONCLUSIONS: Liraglutide seems to reduce GV in the acute phase of acute coronary syndrome, and patients achieved optimal control with a low incidence of hypoglycemia. These results support the need to explore liraglutide in a larger multicenter trial. Trial registration: The study was approved by the National Medical Ethics Committee of Spain. The study was registered at European Clinical Trials Database (EudraCT): 2014003298-40. |
format | Online Article Text |
id | pubmed-7309403 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-73094032020-06-30 Glycemic variability in type 2 diabetes mellitus and acute coronary syndrome: liraglutide compared with insulin glargine: a pilot study del Olmo-García, Maria Isabel Hervás Marín, David Caudet Esteban, Jana Ballesteros Martin-Portugués, Antonio Cerveró Rubio, Alba Arnau Vives, Miguel Angel Catalá Gregori, Ana Penalba Martínez, Maite Merino-Torres, Juan Francisco J Int Med Res Prospective Clinical Research Report OBJECTIVE: To explore the glucagon-like peptide-1 analogue liraglutide in the hospital setting in patients with type 2 diabetes mellitus (T2DM) and acute coronary syndrome and to evaluate the safety and efficacy and its impact on hospitalization and short-term glycemic variability (GV). METHODS: A 12-week, open-label, prospective, randomized pilot clinical study with parallel groups that compared liraglutide (group 1) with glargine (group 2) and its impact on glycemic control and GV. RESULTS: Thirteen patients were included. During hospitalization, mean glucose was 164.75 mg/dL (standard deviation [SD] 19.94) in group 1 and 166.69 mg/dL (38.22) in group 2. GV determined by CV and SD was 20.98 (7.68) vs. 25.48 (7.19) and 34.37 (13.05) vs. 43.56 (19.53) in groups 1 and 2, respectively. Group 1 prandial insulin requirements during hospitalization were lower compared with group 2. Follow-up A1c in group 1 was 6.9% (−1.51%) and 6.5% in group 2 (−1.27). GV after discharge and hypoglycemia were lower in group 1 compared with group 2. CONCLUSIONS: Liraglutide seems to reduce GV in the acute phase of acute coronary syndrome, and patients achieved optimal control with a low incidence of hypoglycemia. These results support the need to explore liraglutide in a larger multicenter trial. Trial registration: The study was approved by the National Medical Ethics Committee of Spain. The study was registered at European Clinical Trials Database (EudraCT): 2014003298-40. SAGE Publications 2020-06-21 /pmc/articles/PMC7309403/ /pubmed/32567433 http://dx.doi.org/10.1177/0300060520926063 Text en © The Author(s) 2020 https://creativecommons.org/licenses/by-nc/4.0/ Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Prospective Clinical Research Report del Olmo-García, Maria Isabel Hervás Marín, David Caudet Esteban, Jana Ballesteros Martin-Portugués, Antonio Cerveró Rubio, Alba Arnau Vives, Miguel Angel Catalá Gregori, Ana Penalba Martínez, Maite Merino-Torres, Juan Francisco Glycemic variability in type 2 diabetes mellitus and acute coronary syndrome: liraglutide compared with insulin glargine: a pilot study |
title | Glycemic variability in type 2 diabetes mellitus and acute coronary syndrome: liraglutide compared with insulin glargine: a pilot study |
title_full | Glycemic variability in type 2 diabetes mellitus and acute coronary syndrome: liraglutide compared with insulin glargine: a pilot study |
title_fullStr | Glycemic variability in type 2 diabetes mellitus and acute coronary syndrome: liraglutide compared with insulin glargine: a pilot study |
title_full_unstemmed | Glycemic variability in type 2 diabetes mellitus and acute coronary syndrome: liraglutide compared with insulin glargine: a pilot study |
title_short | Glycemic variability in type 2 diabetes mellitus and acute coronary syndrome: liraglutide compared with insulin glargine: a pilot study |
title_sort | glycemic variability in type 2 diabetes mellitus and acute coronary syndrome: liraglutide compared with insulin glargine: a pilot study |
topic | Prospective Clinical Research Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7309403/ https://www.ncbi.nlm.nih.gov/pubmed/32567433 http://dx.doi.org/10.1177/0300060520926063 |
work_keys_str_mv | AT delolmogarciamariaisabel glycemicvariabilityintype2diabetesmellitusandacutecoronarysyndromeliraglutidecomparedwithinsulinglargineapilotstudy AT hervasmarindavid glycemicvariabilityintype2diabetesmellitusandacutecoronarysyndromeliraglutidecomparedwithinsulinglargineapilotstudy AT caudetestebanjana glycemicvariabilityintype2diabetesmellitusandacutecoronarysyndromeliraglutidecomparedwithinsulinglargineapilotstudy AT ballesterosmartinportuguesantonio glycemicvariabilityintype2diabetesmellitusandacutecoronarysyndromeliraglutidecomparedwithinsulinglargineapilotstudy AT cerverorubioalba glycemicvariabilityintype2diabetesmellitusandacutecoronarysyndromeliraglutidecomparedwithinsulinglargineapilotstudy AT arnauvivesmiguelangel glycemicvariabilityintype2diabetesmellitusandacutecoronarysyndromeliraglutidecomparedwithinsulinglargineapilotstudy AT catalagregoriana glycemicvariabilityintype2diabetesmellitusandacutecoronarysyndromeliraglutidecomparedwithinsulinglargineapilotstudy AT penalbamartinezmaite glycemicvariabilityintype2diabetesmellitusandacutecoronarysyndromeliraglutidecomparedwithinsulinglargineapilotstudy AT merinotorresjuanfrancisco glycemicvariabilityintype2diabetesmellitusandacutecoronarysyndromeliraglutidecomparedwithinsulinglargineapilotstudy |